Eli Lilly: FDA gives the green light – stock sprints off


Drug manufacturer Eli Lilly received approval from the US Food and Drug Administration for its antidiabetic drug tirzepatid last Friday. After Eli Lilly’s shares had fluctuated sideways in a wide range in the past few weeks, the paper managed a clear breakout at the start of the new trading week on Monday.

The FDA has approved tirzepatide injection, sold under the brand name Mounjaro, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. According to the company, Mounjaro is the first and only FDA-approved glucose-dependent insulinotropic peptide. This is a hormone responsible for stimulating insulin secretion in the B cells of the pancreas.

To make administration easier for patients, Mounjaro will come in Eli Lilly’s auto-injector pen with a pre-attached hidden needle. Patients do not have to see or touch them. In the US, more than 37 million Americans have diabetes. Around 90 to 95 percent of them have type 2 diabetes.


Eli Lilly and Company
(WKN: 858560)

The news is well received by investors. After the papers last fluctuated sideways in the range of 280 to 300 dollars, the share managed a clear liberation on Monday. If the price gains prove to be sustainable, the focus will shift to the record high of $314. The Eli-Lilly share is currently not an ongoing recommendation by the SHAREHOLDER.

Source link

READ
2nd division: FC Hansa Rostock signs midfielder Dressel
Previous Ultra Keto Reviews & Review: Buy Ultra Keto 2022
Next In 3 Days in Cinema: How the Texas Chainsaw Massacre - Only with More Sex: Announcement of New Heritage Horror - Movie News